World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
33557
World Ranking
12570
National Ranking
478

Stefano Cascinu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stefano Cascinu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,076 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stefano Cascinu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stefano Cascinu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stefano Cascinu is affiliated with Vita-Salute San Raffaele University in Italy. Their research primarily focuses on the field of Medicine, with a significant concentration in Oncology, Surgery, Pulmonary and Respiratory Medicine, Hepatology, and Cancer Research.

The main topics covered by their work include:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer

Stefano Cascinu has contributed to publications in a variety of academic journals. The most frequent venues include:

  • Annals of Oncology
  • Targeted Oncology
  • Cancers
  • European Journal of Cancer
  • HPB

Some recent papers with details on their publication year and venue are:

  • Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis, 2022, ESMO Open
  • Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population, 2022, European Journal of Cancer
  • Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data, 2023, Liver International
  • Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes, 2020, The Oncologist

The scientist frequently collaborates with other researchers. The most common coauthors associated with their work are:

  • Andrea Casadei-Gardini
  • Mario Scartozzi
  • Margherita Rimini
  • Sara Lonardi
  • Valentina Burgio

Best Publications

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

  • Addressing the challenges of pancreatic cancer: future directions for improving outcomes

    Manuel Hidalgo;Stefano Cascinu;Jörg Kleeff;Roberto Labianca

  • Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

    Timothy J Price;Marc Peeters;Tae Won Kim;Jin Li

  • PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

    Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo

  • Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

    E. Van Cutsem;M. Nowacki;I. Lang;S. Cascinu

  • Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente)

    E. Mari;I. Floriani;A. Tinazzi;A. Buda

  • Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

    Stefano Cascinu;Vincenzo Catalano;Luigi Cordella;Roberto Labianca

  • Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)

    C. Pinto;F. Di Fabio;S. Siena;S. Cascinu

  • Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

    Andrea Sartore-Bianchi;Mauro Moroni;Silvio Veronese;Carlo Carnaghi

  • Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

    M. Scartozzi;E. Galizia;S. Chiorrini;R. Giampieri

  • PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

    F Massari;M Santoni;C Ciccarese;D Santini

  • Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

    Mario Scartozzi;Italo Bearzi;Rossana Berardi;Alessandra Mandolesi

  • Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.

    Stefano Cascinu;Maria Pia Staccioli;Giampietro Gasparini;Paolo Giordani

  • The evolving role of microsatellite instability in colorectal cancer: A review.

    Fabio Gelsomino;Monica Barbolini;Andrea Spallanzani;Giuseppe Pugliese

  • Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.

    S Cascinu;A Fedeli;E Del Ferro;S Luzi Fedeli

  • Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

    D. Santini;B. Vincenzi;R. Addeo;C. Garufi

  • Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)

    C. Pinto;F. Di Fabio;C. Barone;S. Siena

  • Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    S. Cascinu;M. Falconi;Vincenzo Valentini;S. Jelic

  • Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy

    Annamaria Ruzzo;Francesco Graziano;Kazuyuki Kawakami;Go Watanabe

  • Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.

    Stefano Cascinu;Carlo Aschele;Sandro Barni;Domizia Debernardis

Frequent Co-Authors

Daniele Santini
Daniele Santini Università Campus Bio-Medico
Alfredo Falcone
Alfredo Falcone University of Pisa
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Roberto Labianca
Roberto Labianca Mario Negri Institute for Pharmacological Research
Rodolfo Montironi
Rodolfo Montironi Marche Polytechnic University
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Vittorina Zagonel
Vittorina Zagonel Mario Negri Institute for Pharmacological Research
Nicola Silvestris
Nicola Silvestris University of Messina
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Massimo Falconi
Massimo Falconi Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine or healthcare, a variety of related online degrees and career pathways are available. These online programs offer flexibility and a range of specializations to suit differing career goals. If you are pursuing nursing, consider exploring asn to fnp programs to efficiently advance from an associate’s degree in nursing toward becoming a family nurse practitioner.

Those passionate about nutrition or wellness can start their healthcare careers with a bachelor's in nutrition online, preparing for roles in education, research, or health promotion. Accreditation is another critical issue—if you’re considering health administration, it’s essential to ask which online healthcare degree programs are recognized for their accreditation by cahme? to ensure your degree meets industry standards.

For registered nurses who want to advance, some schools now offer online rn-bsn programs without clinicals. These options provide a flexible, accessible way to upgrade qualifications and expand job opportunities without the need for in-person clinical requirements. Exploring these alternatives can provide a fulfilling and adaptable path in the growing healthcare sector.

Best Scientists Citing Stefano Cascinu

Trending Scientists

Recently Published Articles